



**SOLVAY**

asking more from chemistry®

# Q4 & FY 2013 results

February 26, 2014

# 2013 overview

- Acceleration of Solvay's transformation
- Delivery in a challenging economic context
- Strong fundamentals to create value



**SOLVAY**

asking more from chemistry®

## Forenote

All references to 2012 Income Statement data are restated for:

- the Group's new business organization effective as from January 1, 2013;
- the application of IAS 19 revised;
- the Group's European Chlorovinyls activities planned to be contributed to the JV with Ineos.

The European Chlorovinyls business activities are reflected as "Assets Held For Sale" on the balance sheet (in one single line) and as discontinued operations in the Income Statement as required by IFRS.

As from December 31, 2013, Benvic (the PVC compounding business) is reflected in the Balance Sheet as "Assets Held for Sale", but as continued operations in the Income Statement.

Chemlogics is consolidated in the financial statements from November 1, 2013.

Furthermore, Solvay is presenting Adjusted Income Statement performance indicators that exclude non-cash Purchase Price Allocation (PPA) accounting impacts related to the Rhodia acquisition.

# 2013 overview

- **Acceleration of Solvay's transformation**
- Delivery in a challenging economic context
- Strong fundamentals to create value



**SOLVAY**

asking more from chemistry®

# An in-depth transformation

## our Vision

- Build a **strong global leader** in the chemical industry
- Be a model of **sustainable chemistry**
- Become a **high growth, less capital intensive & high return** Group

- Reinforcing business profile through **strategic portfolio upgrades**
- Striving for **excellence** across businesses
- Innovating to create **sustainable solutions**
- Transforming **company culture** with a focus on performance

## our Strategy



# Business profile enhanced through strategic portfolio upgrades

2013

## Reduced cyclicity through phased disposals

- **European Chlorovinyls** activities to be contributed to **JV** with Ineos
- **Indupa** to be sold to Braskem
- **Benvic** divestment in progress

## Extended customer solutions offering


- **Chemlogics** acquisition: Strong start to synergies delivery
- Investing in **growth engines** and innovation capabilities



Portfolio upgrade to continue

# Footprint enhanced, poised for more growth

## Rebalanced geographic exposure\*



\*Figures represent % of 2013 net sales (pro-forma Chemlogics)  
% evolution vs 2012

## Enhanced exposure to higher growth end-markets\*



# Excellence initiatives embedded in the organization

## Manufacturing excellence

- Variable & fixed cost reductions
- Overall Equipment Efficiency

## Purchasing, supply chain & logistical excellence

## Commercial excellence

## Innovation excellence

**>120 major programs initiated**

### Energy efficiency

- Reducing 2020 energy consumption by 10% vs 2012
- > € 100 m by YE 2016




### Soda ash and Polyamide improvement plans

- Reinforcing Soda Ash global leadership and competitiveness in Europe: € 100m by YE 2015
- Restoring Polyamide profitability and regaining strategic flexibility: € 100 m by YE 2014

### Building best-in-class global business services

**Unlocking value growth: € 670 m by YE 2016**

# Innovative sustainable solutions launched



## Main 2013 achievements

### Innovative products launch

- Bio-based products: Ocalio, Starguar, Kalix®, ...
- High performance products : Technyl® One, Kalix® HFFR, ...

### Open innovation initiatives

- Participation in AONIX (Canada): Accelerate development & commercialization of mass-produced thermoplastic composites
- Partnership with Granbio (Brazil): Development of bio-based n-butanol for use in green solvents


### New R&I facility in Shanghai

- 130 researchers
- Supporting all businesses in Asia





# Focus on performance



# 2013 overview

- Acceleration of Solvay's transformation
- **Delivery in a challenging economic context**
- Strong fundamentals to create value



**SOLVAY**

asking more from chemistry®

# FY 2013 financial highlights

- Forex headwinds
- Raw materials deflation
- Volume decrease primarily related to CER phase-out

Net Sales

**€ 9.9 bn**

(5)% yoy

- CER phase-out and guar effect exceptionals
- Pricing power preserved
- Excellence programs delivering

REBITDA

**€ 1,663 m**

(12)% yoy

Stable allowing for exceptionals & Chemlogics

- Significant non-recurring costs € (239) m (e.g. restructuring for integration and excellence)

Net Income

**€ 378 m**

Adjusted, Group Share

- Strong Free Cash Flow
- Industrial working capital of 12.4%

FCF

**€ 524 m**

**Stable dividend proposed at**


**€ 3.20**  
gross / share



# Stable underlying results allowing for exceptionals


## Net Sales

in € m



## REBITDA

in € m



Conversion effects primarily from USD, JPY and BRL devaluations vs EUR

Exceptional elements impacted REBITDA by ~€ (240) m

- ~ € (90) m of CER anticipated phase-out
- ~ € (100) m from native guar peak prices in 2012
- ~ € (50) m from guar derivatives margin impact

Pricing power preserved thanks to portfolio quality and excellence initiatives


Fixed cost inflation partially mitigated

# Underlying operational performance flat, growth engine impacted by exceptionals

## REBITDA 2013

in € m

### Advanced Formulations



### Essentially flat, allowing for exceptionals

- Successful integration of Chemlogics, with strong start to synergies delivery
- Guar conditions stabilized
- Resilience in Coatis and Aroma Performance


### Record performance

- Record performance at Specialty Polymers and Silica
- Performance stabilization at Rare Earths with an end to previous margin squeeze
- Special Chemicals' refocused portfolio enhancing profitability

### Advanced Materials



### Functional Polymers




### Restoring profitability

- Challenging trading conditions persisted in Polyamide & Intermediates
- Structural repositioning at Engineering Plastics
- Divestment process for European Chlorovinyls activities on-going

### Overall resilience

- Essential Chemicals' resilient results proving sustainability
- Record performance at Acetow
- Eco Services resilient; strategic options being explored
- Poor demand at Emerging Biochemicals

### Performance Chemicals



REBITDA 2013\*

\* Energy Services in purple, excluding Corporate costs



# Non-cash one-offs reduce net income

In € m

Adjusted* P&L	2012	2013
<b>Net sales</b>	<b>10,515</b>	<b>9,938</b>
<b>REBITDA</b>	<b>1,896</b>	<b>1,663</b>
Depreciation & Amortization + other elements	(593)	(628)
<b>REBIT</b>	<b>1,303</b>	<b>1,035</b>
Non-recurring items	55	(239)
<b>EBIT</b>	<b>1,357</b>	<b>796</b>
Net financial charges	(362)	(210)
Income taxes	(291)	(229)
Discontinued operations	1	65
<b>Net Income</b>	<b>707</b>	<b>422</b>
of which Solvay share	690	378

## Depreciation & Amortization and other elements

- Recurring Depreciation & Amortization of € (603) m
- Other elements relate to pre-operational forex effect on Rusvynyl debt and temporary Chemlogics inventory step-up and retention plan

## Non-recurring rose due to non-cash elements

- Restructuring costs largely flat at € (115) m, primarily linked to integration and Soda Ash restructuring
- Non-cash elements include impairments € (65) m on Plextronics and Benvic

## Net financial charges lower

- Higher discount rates reduced environmental provisions
- Capital gain on disposal of a non-core financial investment

## Higher contribution from discontinued operations


- Last milestone payment from divested pharma business more than offset impairment on Indupa

\* Adjusted: Excluding non-cash PPA accounting impacts related to the Rhodia acquisition

# Strong Free Cash Flow generation

## Net debt evolution


in € m




## Focus on cash generation

# Selective investments for value growth


**Capex**  
(in € m)



1/3 Resilient & cyclical businesses  
2/3 Growth engines




**Focused on  
superior growth areas**



# Sustained performance in Working Capital efficiency

## Industrial Working Capital / Total Sales




\* Restated to exclude discontinued operations

# A sound balance sheet

## Capital structure

YE 2013

in € bn



## Strong credit ratios

YE 2013

**Gearing**  
(Net debt / Equity)

**15%**

**49%**  
Including  
pension  
provisions

**Leverage**  
(Net debt / REBITDA)

**0.66x**

**2.19x**  
including  
pension  
provisions


Significant upcoming debt repayments to bolster efficiency

Repayments in 2014-2015 → over € 1.5 bn

Cost of carry to be halved by 2015



# Stable total dividend proposed



2013

**€ 3.20 / share**

(gross) dividend proposed

- € 1.33 interim dividend paid in January 2014
- € 1.87 balance to be paid in May 2014

## Committed to stable / growing dividend

# 2013 overview

- Acceleration of Solvay's transformation
- Delivery in a challenging economic context
- **Strong fundamentals to create value**



**SOLVAY**

asking more from chemistry®

# Transformation will continue



- Complete initiated portfolio upgrades
- Explore further strategic options
- Grow with our customers
- Sustain focus on excellence

**Asking more from chemistry**

# 2014 outlook

Some end-markets show early signs of improvement

Solvay well-placed to benefit from an upswing in macroeconomic conditions

Excellence programs will deliver in coming years



Although cautious, Solvay is confident that 2014 will show **REBITDA growth**

# Take-aways



Progress on  
many fronts



Poised  
for growth



On track towards  
2016 targets

**REBITDA to reach € 2.3 – 2.5 bn**

REBITDA margin to reach 18%

**CFROI to increase by > 100 bp vs 2013\***

2/3 of businesses in value-creation zone



**2016**

\* Prior to discontinued operations



# Safe harbour

To the extent that any statements made in this presentation contain information that is not historical, these statements are essentially forward-looking. The achievement of forward-looking statements contained in this presentation is subject to risks and uncertainties because of a number of factors, including general economic factors, interest rate and foreign currency exchange rate fluctuations; changing market conditions, product competition, the nature of product development, impact of acquisitions and divestitures, restructurings, products withdrawals; regulatory approval processes, all-in scenario of R&D projects and other unusual items.

Consequently, actual results may differ materially from those expressed or implied by such forward-looking statements.

Forward-looking statements can be identified by the use of words such as "expects," "plans," "will," "believes," "may," "could" "estimates," "intends", "goals", "targets", "objectives", "potential", and other words of similar meaning. Should known or unknown risks or uncertainties materialize, or should our assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly update any forward-looking statements.

# Calendar

<b>March 31, 2014</b>	Annual report (on website)
-----------------------	----------------------------

<b>May 6, 2014</b>	Q1 results publication
--------------------	------------------------

<b>May 13, 2014</b>	AGM
---------------------	-----

<b>May 15, 2014</b>	Ex-dividend trading date
---------------------	--------------------------

<b>May 20, 2014</b>	Dividend payment (balance)
---------------------	----------------------------

<b>July 31, 2014</b>	Q2 results publication
----------------------	------------------------

<b>November 13, 2014</b>	Q3 results publication
--------------------------	------------------------



# Annexes

- Q4 & FY 2013 Group results
- Q4 & FY 2013 segment results
- Considerations for 2014
- 2016 ambition
- Segment presentation



**SOLVAY**

asking more from chemistry®

# Annexes

- **Q4 & FY 2013 Group results**
- Q4 & FY 2013 segment results
- Considerations for 2014
- 2016 ambition
- Segment presentation



**SOLVAY**

asking more from chemistry®

# Q4 2013 financial highlights

- Forex headwinds
- Raw materials deflation
- Chemlogics 2 months contribution

Net Sales

**€ 2.4 bn**

(5)% yoy

- CER phase-out and guar effect exceptionals
- Pricing power preserved
- Excellence programs delivering

REBITDA

**€ 384 m**

(6)% yoy

Up 8% allowing for exceptionals & Chemlogics

- Significant non-recurring costs € (68) m related to non-cash impairments (portfolio upgrade)

Net Income

**€ 25 m**

Adjusted, Group Share

- Strong Free Cash Flow
- Industrial working capital of 12.4%

FCF


**€ 246 m**



# Q4 2013 Net sales and REBITDA

## Net Sales

in € m




Net Sales decreased primarily due to forex headwinds and raw materials deflation

Volume decrease fully due to CER phase-out

Chemlogics 2 months contribution added 3% to net sales and 4% to REBITDA

## REBITDA

in € m



REBITDA decreased by (6)%; Underlying REBITDA grew by 8% allowing for CER phase-out, guar exceptionals and Chemlogics

Pricing power and REBITDA margin largely stable

# Q4 2013 net income

In € m

Adjusted* P&L	2012	2013
<b>Net sales</b>	<b>2,541</b>	<b>2,417</b>
<b>REBITDA</b>	<b>407</b>	<b>384</b>
Depreciation & Amortization + other elements	(157)	(184)
<b>REBIT</b>	<b>250</b>	<b>200</b>
Non-recurring items	92	(68)
<b>EBIT</b>	<b>342</b>	<b>131</b>
Net financial charges	(86)	(18)
Income taxes	(77)	(84)
Discontinued operations	(4)	1
<b>Net Income</b>	<b>176</b>	<b>29</b>
of which Solvay share	198	25

\* Adjusted: Excluding non-cash PPA accounting impacts related to the Rhodia acquisition

## Depreciation & Amortization and other elements

- Recurring Depreciation & Amortization of € (164) m
- Other elements relate to pre-operational forex effect on Rusvinyl debt and temporary Chemlogics inventory step-up and retention plan

## Non-recurring rose due to non-cash elements

- Restructuring costs at € (14) m
- Non-cash elements include impairment € (32) m on Benvic
- 2012 included € 139 m positive impairment reversal in Soda Ash

## Net financial charges lower

- Higher discount rates in 2013 reduced NPV environmental provisions; the reverse was true in 2012
- Capital gain of € 40 m on disposal of a non-core financial investment in 2013


## Higher contribution from discontinued operations

- Last milestone payment from divested pharma business of € 100 m more than offset impairment on Indupa

# Q4 2013 Net Debt evolution


## Net Debt evolution

in € m



# Portfolio actions and excellence delivery overcome exceptionals

## CFROI



## Cash Flow Return On Investment

$$\text{CFROI} = \frac{\text{REBITDA} - \text{Rec. Capex} - \text{Tax}}{\text{Gross assets} + \text{Working Capital}}$$

- Demanding value-based framework for strategic decision making
- Provides insight on capital allocation
- Based on actualised investment costs rather than historic ones
- Key metric to determine real economic value creation

**Raising the CFROI towards WACC by 2016**

# Balance sheet

In € m


Balance sheet	YE 2012	YE 2013
Fixed assets	9,572	9,395
Investment & shares	1,057	1,036
Loans and other non current financial receivables / payables	209	91
Assets held for sale	425	1,621
Taxes payable/receivable + Others	3	51
Working capital	1,379	1,216
<b>Total invested capital</b>	<b>12,645</b>	<b>13,411</b>
Equity	6,573	7,453
Provisions	4,507	3,796
Dividends	103	111
Net financial debt	1,125	1,102
Liabilities related to assets held for sale	337	949
<b>Total financing</b>	<b>12,645</b>	<b>13,411</b>

# Pension liabilities

## Net pension liabilities

YE 2013

in € m



- Net pension liability  
75% denominated in EUR
- Stable cash contribution in 2013  
of € (186) m
- Discount rate used at YE 2013  
of 3.88% weighted average\*
  - EUR: 3.25%
  - GBP: 4.50%
  - USD: 4.75%
- Pension assets of € 1,925 m at YE
  - 50% Equities / Diversified alternative funds
  - 50% Bonds / Real estate

\* Versus 3.63% weighted average at YE 2012

# Annexes

- Q4 & FY 2013 Group results
- **Q4 & FY 2013 segment results**
- Considerations for 2014
- 2016 ambition
- Segment presentation



**SOLVAY**


asking more from chemistry®

# Advanced Formulations impacted by guar price developments

## Net sales

FY 2013  
**€ 2,432 m**  
(5)% yoy


Q4 2013  
**€ 644 m**  
(0)% yoy



## REBITDA

FY 2013  
**€ 369 m**  
(29)% YoY

Q4 2013  
**€ 87 m**  
(16)% YoY



## Novecare

- Successful integration of Chemlogics and strong start to synergies delivery
- Back to stable guar demand conditions at YE, after significant setbacks
- Encouraging demand growth in Agro and Coatings
- Impact from exceptionals 2013 vs 2012 of ~ € (150) m

## Coatis

- Positive pricing power supported by BRL devaluation and sales indexed in USD

## Aroma Performance

- Resilient food and pharma markets




# Strong results at Advanced Materials

## Net sales

FY 2013  
**€ 2,551 m**  
(7)% yoy

Q4 2013  
**€ 603 m**  
(4)% yoy



## Specialty Polymers

- Record performance

## Silica

- Record performance

## Rare Earth Systems

- Performance stabilization as market price declines slowed by YE


## Special Chemicals

- Refocused portfolio enhancing profitability with successful Life Science strategic exit

## REBITDA

FY 2013  
**€ 646 m**  
3% yoy

Q4 2013  
**€ 160 m**  
18% yoy




# Resilient cash generation by Performance Chemicals

## Net sales

FY 2013  
**€ 3,125 m**  
(1)% yoy


Q4 2013  
**€ 784 m**  
(2)% yoy



## REBITDA

FY 2013  
**€ 724 m**  
(3)% yoy

Q4 2013  
**€ 186 m**  
4% yoy



## Essential Chemicals

- Resilience of results proving sustainability

## Acetow

- Record performance

## Eco Services

- Resilient performance
- Strategic options being explored

## Emerging Biochemicals


- Poor demand in both Chlorovinyls and Epichlorohydrin

# Challenging conditions for Functional Polymers

## Net sales

FY 2013  
**€ 1,763 m**  
(7)% yoy

Q4 2013  
**€ 384 m**  
(10)% yoy



## Polyamide

- Persistent challenging trading conditions in Polyamide & Intermediates
- Improved performance at Engineering Plastics following structural repositioning


## Chlorovinyls

- Classification of “Discontinued Operations” of European activities related to JV project with Ineos
- Classification of Benvic PVC compounds as “Assets Held for Sale” with advanced stage in the divestment process. Results stable, reported in continued operations

## REBITDA

FY 2013  
**€ 93 m**  
(7)% yoy

Q4 2013  
**€ 14 m**



# Annexes

- Q4 & FY 2013 Group results
- Q4 & FY 2013 segment results
- **Considerations for 2014**
- 2016 ambition
- Segment presentation



**SOLVAY**

asking more from chemistry®

# REBITDA considerations for 2014

- **Carbon emission rights**

- Carbon Emission Rights (CER) scheme came to an end in 2013
- Total sales of CERS: € 58 m in H1 2013

- **Rusvinyl** ramp-up

- PVC plant in Russia, JV with Sibur
- Planned commissioning and subsequent ramp-up in H2

# Financial charges considerations for 2014

- **Debt repayments** for € 1 bn in the year, € 1.5 bn by 2015
  - € 500 m in January 2014
  - € 500 m in May 2014 (call option on high-yield bond 2018)
  - € 500 m in 2015

Lead to a reduction of **net interest charges**

⇒ Average gross interest rate to reduce by 40 bp to 4.9%

⇒ Cost of carry on cash to decrease following reduced cash position

- **Discounting costs** on provisions, at YE 2013 rates
  - Environmental provisions: ~ € 30 m
  - Pensions: ~ € 100 m

# Hybrid bond

- Nominal value of € 1.2 bn, at initial average dividend yield of 4.7%
  - € 0.5 bn at 5.425%
  - € 0.7 bn at 4.199%
- Dividends from hybrid bond will be accounted for in equity
  - ⇒ Income statement:  
No impact
  - ⇒ Statement of financial position:  
Treated under Equity
  - ⇒ Statement of cash flows:  
Treated as dividend in Cash flow from financing activities

# Other considerations for 2014

- **Depreciation & Amortization**
  - Recurring Depreciation & Amortization: ~€ 650 m
  - Rhodia PPA impact: ~€ 120 m
- **Restructuring costs** expected to be lower
- Recurring **tax rate** mid to low 30s over 2014-2016
- **Discontinued operations**, expected to reach completion in 2014
  - **Indupa sale to Braskem** to add negative result of currency translation adjustments for ~ € 50 m (situation YE 2013) at deal closing
  - **Chlorovinyls JV with Ineos** will be treated as equity associate upon JV effectiveness



# Annexes

- Q4 & FY 2013 Group results
- Q4 & FY 2013 segment results
- Considerations for 2014
- **2016 ambition**
- Segment presentation



**SOLVAY**

asking more from chemistry®

# Solvay, a major global chemical player

**€ 9.9 bn**

Net Sales

**€ 1.7 bn**

REBITDA

**16.7%**

REBITDA margin

**€ 378 m**

Adjusted Net Income,  
Group share

## Based on strengths



Well-balanced geographical spread and end-user markets



Leading player in 90% of our businesses



Strong R&I portfolio

## And with ambition

**117**

Industrial sites

**15**

Major R&I centers

**29,400**

Employees (EFTEs)


**56**

Country presence

All figures excluding discontinued operations, except for employees


# Well-balanced geographical spread and end-user markets

## Balanced geographic exposure\*



\* Figures represent % of 2013 net sales (pro-forma Chemlogics)

## Exposure to higher growth end-markets\*



# 90% of our business ranking among top 3 players

1


ADVANCED FORMULATIONS	Specialty surfactants	PERFORMANCE CHEMICALS	Hydrogen peroxide
	Diphenols		Soda ash
	Phosphorus chemistry		Bicarbonate
ADVANCED MATERIALS	High-performance engineering polymers & compounds	Fluorinated polymers	Rare earth formulations
		High-barrier polymers	High-dispersible silica

3

FUNCTIONAL POLYMERS	PA 6.6 polymers & intermediates	PERFORMANCE CHEMICALS	Cellulose acetate fiber
	PA 6.6 engineering plastics		

# Strong innovation portfolio aligned with global megatrends

## Focused innovation fields



2013

**15**

Major R&I sites worldwide

**1,950**

R&I staff

**€ 280 m**

R&I efforts

**22%**

New sales ratio

**252**

Patents filed

# Converting vision into value

## Our strategy

- Reinforcing business profile through strategic portfolio changes
- Striving for excellence across businesses
- Innovating to create sustainable solutions
- Transforming company culture with a focus on performance

## Our 2016 ambition

**REBITDA to reach € 2.3 - 2.5 bn**

→ **REBITDA margin to reach 18%**

**CFROI to increase by >100 bp vs 2013**

→ **2/3<sup>rd</sup> of businesses in value-creation zone**

**Being a model of sustainability**

→ **Reducing our impact on environment**

# A business portfolio change

## Executing our strategic action plan

**2010**

Pharma divestiture

**2011**

Rhodia acquisition

**2012**

### INTEGRATION

- Integration & definition of new strategic priorities
- Alignment of corporate & business structure
- Renew management And people model

**2013**


### TRANSFORMATION

- Chlorovinyls Europe JV announcement
- Solvay Indupa divestiture
- Chemlogics acquisition

### LAUNCHING EXCELLENCE INITIATIVES

- Polyamide breakthrough performance improvement plan
- Soda Ash breakthrough performance improvement plan

## To enhance our business profile



# REBITDA growth supported by strong operational levers

REBITDA

in € m

1,663\*

Chemlogics  
(10 months)

Inflation

(260)

Operational  
excellence

300

Organic  
growth

280

Market  
growth

Innovation

250

Portfolio

2,300-2,500

> 10% CAGR

Manufacturing  
Excellence  
230

Excellence  
programs  
670

Variable  
& fixed cost  
reductions

Purchasing,  
supply & other  
efficiencies

Overall  
Equipment  
Efficiency

Commercial  
Excellence

Innovation  
Excellence

2013

2016e

REBITDA  
margin  
16.7%

REBITDA  
margin  
18%


\* Chemlogics consolidated for 2 months



# Enhanced quality of earnings across segments with differentiated levers throughout our businesses


REBITDA

in € m



# Unlocking value by increasing CFROI and REBITDA margin


2012



CFROI  
to increase by  
100bp

REBITDA margin  
to reach  
18%

2016



● GBUs ● Solvay

Bubble Size indicates REBITDA (in € bn)

$$\text{CFROI} = \frac{\text{REBITDA} - \text{Rec. Capex} - \text{Tax}}{\text{Gross assets} + \text{Working Capital}}$$

$$\text{Premium return} = \text{WACC} + 150\text{bp}$$

# Focused on being a model of sustainability taking commitments

SOLVAY way



Planet



Customers



Investors



Suppliers




Communities



Employees

- Reach excellence in safety & health
- Deploy unmatched sustainable portfolio management
- Reduce our impact on environment by 2020



- Manage risk
- Develop rich & balanced social dialogue

## Providing sustainable solutions




Dow Jones  
Sustainability Indexes  
Member 2012/13



# Executing a clear value creation strategy

**Towards a higher growth,  
improved cash generation  
& enhanced returns  
Chemical Group**

**Targeting Sustainable  
Value Growth**



# Annexes

- Q4 & FY 2013 Group results
- Q4 & FY 2013 segment results
- Considerations for 2014
- 2016 ambition
- **Segment presentation**



**SOLVAY**

asking more from chemistry®

# New organisation set-up

	Advanced Formulations	Advanced Materials	Performance Chemicals	Functional Polymers	Corporate & Business Services
	<div>Novecare</div> <div>Aroma Performance</div> <div>Coatis</div>	<div>Specialty Polymers</div> <div>Silica</div> <div>Rare Earth Systems</div> <div>Special Chemicals</div>	<div>Soda Ash &amp; Derivatives*</div> <div>Peroxide*</div> <div>Acetow*</div> <div>Eco-Services</div> <div>Emerging Biochemicals</div>	<div>Polyamide</div> <div>P&amp;I</div> <div>Engineering Plastics</div> <div>Fibras</div>	<div>Solvay Energy Services</div> <div>Corporate Functions</div>
2013					
Net Sales	€ 2,432 m	€ 2,551 m	€ 3,125 m	€ 1,763 m	€ 67 m
REBITDA	€ 369 m	€ 646 m	€ 724 m	€ 93 m	€ (169) m
REBITDA margin	15%	25%	23%	5%	n.m.

\* Up to end 2013 forming GBU Essential Chemicals

# Advanced Formulations

€ 2,432 m


Net Sales 2013

€ 369 m


REBITDA 2013



## Net sales



by GBU



by geography

As growth engines for Solvay, the **Advanced Formulations** activities are characterized by their strong capacity for innovation and their low capital intensity.

In line with the major trends in society, their offerings contribute to advances in mass consumer markets, the environment and energy.


# Advanced Materials

€ 2,551 m


Net Sales 2013

€ 646 m


REBITDA 2013



## Net sales



by GBU



by geography

A leader in markets with high entry barriers and high returns on investment, the **Advanced Materials** segment is a major contributor to the Group's performance and growth.

The innovation capacities of its various activities, their global presence and the long-term partnerships they have forged with customers give them a clear competitive edge with industries that are seeking ever less energy-consuming and polluting functionalities.



# Performance Chemicals

€ 3,125 m

Net Sales 2013

€ 724 m

REBITDA 2013

Soda Ash &  
Derivatives



Peroxides

Acetow

Eco  
Services

Emerging  
Bio-  
chemicals

## Net sales



**Performance Chemicals** operates in specific, highly resilient and mature markets whose key success factors are principally economies of scale, competitiveness and quality of service.

Solidly cash-generating, its activities of the are engaged in new programs of excellence to create sustainable value.

# Functional Polymers

€ 1,763 m


Net Sales 2013

€ 93 m


REBITDA 2013



## Net sales



by GBU



by geography

As part of its portfolio optimization strategy, the Group has refocused **Functional Polymers** on the polyamide chain. Solvay is one of the few players to control the entire polyamide 6-6 chain.

Given the cyclical nature of its markets, the GBUs in this segment have launched major competitiveness enhancement programs. They have also opened new markets with by launching innovative solutions.

# Corporate & Business Services

€ 67 m

Net Sales 2013

€ (169) m

REBITDA 2013



**Corporate & Business Services** includes the GBU Energy Services offering of energy optimization programs for the Group and for third parties.

It also includes the "Corporate" functions that are responsible with GBUs for defining and deploying transversal policies that guarantee consistency within the Group. Further, Solvay Business Services, handles all the Group's IT and business processes.

[www.solvay.com](http://www.solvay.com)



**SOLVAY**

asking more from chemistry®